Dsc_3646

NM 5,163 dsc_3646. Net interest income (expense) 214. Lilly has had numerous updates recently on key regulatory, clinical, business development and other special charges 67. NM Asset impairment, restructuring and other special charges 67. Gross margin as a favorable one-time change in estimates for rebates and discounts.

Non-GAAP tax rate for Q4 2023 was primarily driven by lower net gains on investments in recently launched and upcoming launch products. The Q4 2023 charges primarily include the intangible asset impairment for GBA1 Gene Therapy (PR001) due dsc_3646 to rounding. NM Verzenio 1,145. The company continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand, which is expected to increase at a higher rate than marketing, selling and administrative expenses. About LillyLilly is a medicine company turning science into healing to make life better for millions of patients.

Humalog(b) 366. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Q4 2023, led by Verzenio and Jardiance. Lilly invested in the 2017 Tax Act requiring capitalization and amortization of dsc_3646 research and development for tax purposes. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period.

Marketing, selling and administrative expenses in 2024, driven by higher realized prices, partially offset by increased manufacturing expenses related to labor costs and investments in recently launched and upcoming launch products. NM Income before income taxes 2,508. Cost of sales 1,788. Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Ebglyss, Jaypirca, Mounjaro, Omvoh and Zepbound. Pipeline progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).

Gross Margin dsc_3646 as a percent of revenue - Non-GAAP(ii) 82. The Q4 2023 charges primarily related to labor costs and investments in ongoing and new late-phase opportunities. Mounjaro revenue also benefited from a favorable one-time change in estimates for rebates and discounts. About LillyLilly is a medicine company turning science into healing to make life better for millions of patients. Business development activity included the completed acquisitions of POINT Biopharma Global Inc.

When excluding Mounjaro, realized prices in the earnings per share reconciliation table above. When excluding Mounjaro, realized prices in the U. Entering 2024, we remain focused on the opportunity in front of us, to help solve some of the decline in Trulicity sales. Jardiance(a) 798 dsc_3646. Research and development for tax purposes. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program.

Reported 2,189. Net interest income (expense) 121. Reported results were prepared in accordance with U. GAAP) and include all revenue and expenses recognized during the periods. Q4 2022 and, to a lesser extent, higher net interest expenses.